Alpha Tau Medical (NASDAQ:DRTS) Trading Up 2.1% - What's Next?

Key Points

• Alpha Tau Medical's stock price increased by 2.1% on Thursday, trading as high as $3.93 before closing at $3.83 with a volume increase of 74% from the average.
• HC Wainwright reaffirmed a "buy" rating with a price target of $9.00 for Alpha Tau Medical, which currently holds an average rating of "Buy" among analysts.
• The company reported a loss of ($0.13) earnings per share in its recent quarterly earnings, below analysts' expectations of ($0.12).

Alpha Tau Medical Ltd. (NASDAQ:DRTS - Get Free Report)'s stock price was up 2.1% on Thursday . The stock traded as high as $3.93 and last traded at $3.83. Approximately 108,494 shares changed hands during trading, an increase of 74% from the average daily volume of 62,361 shares. The stock had previously closed at $3.75.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a "buy" rating and issued a $9.00 price target on shares of Alpha Tau Medical in a research note on Wednesday, September 3rd. One equities research analyst has rated the stock with a Buy rating, According to MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $9.00.

Alpha Tau Medical Price Performance

The company has a debt-to-equity ratio of 0.07, a quick ratio of 5.81 and a current ratio of 10.52. The company has a 50-day moving average of $3.25 and a 200-day moving average of $2.95. The firm has a market capitalization of $324.86 million, a price-to-earnings ratio of -7.98 and a beta of 1.00.

Alpha Tau Medical (NASDAQ:DRTS - Get Free Report) last released its quarterly earnings results on Monday, August 11th. The company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.01). As a group, research analysts anticipate that Alpha Tau Medical Ltd. will post -0.45 EPS for the current fiscal year.

Institutional Investors Weigh In On Alpha Tau Medical

A number of large investors have recently added to or reduced their stakes in the business. Kovitz Investment Group Partners LLC raised its stake in Alpha Tau Medical by 601.4% in the 1st quarter. Kovitz Investment Group Partners LLC now owns 226,320 shares of the company's stock valued at $568,000 after acquiring an additional 194,055 shares during the period. Northern Trust Corp increased its position in Alpha Tau Medical by 112.6% during the 4th quarter. Northern Trust Corp now owns 48,666 shares of the company's stock worth $151,000 after buying an additional 25,770 shares during the period. Finally, XTX Topco Ltd bought a new position in Alpha Tau Medical during the 1st quarter worth $53,000. Institutional investors own 2.65% of the company's stock.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.